marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2025-Q2
added 08-01-2025
Fulgent Genetics Market Cap 2011-2025 | FLGT
As of October 09, 2025 Fulgent Genetics has a market cap of $ 690 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 467 M | 701 M | 993 M | 1.83 B | 2.3 B | 253 M | 69.2 M | 85.1 M | 225 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.3 B | 69.2 M | 769 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Danaher Corporation
DHR
|
152 B | $ 204.96 | -1.82 % | $ 150 B |  USA |
 |
Centogene N.V.
CNTG
|
221 M | $ 0.33 | -6.23 % | $ 30.6 M |  Germany |
 |
Fluidigm Corporation
FLDM
|
481 M | $ 3.75 | 1.08 % | $ 308 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | $ 2.99 | - | $ 399 M |  China |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | $ 21.99 | - | $ 562 M |  Britain |
 |
Genetron Holdings Limited
GTH
|
1.54 B | $ 4.03 | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
6.47 B | $ 53.55 | 3.3 % | $ 3.71 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | $ 0.46 | 0.22 % | $ 16.8 M | USA |
 |
Medpace Holdings
MEDP
|
10.2 B | $ 531.0 | -0.16 % | $ 16.4 B | USA |
 |
Meridian Bioscience
VIVO
|
1.35 B | $ 33.97 | - | $ 1.49 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | $ 0.48 | -20.0 % | $ 1.06 M | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 5.82 | 4.11 % | $ 1.26 B | USA |
 |
Quotient Limited
QTNT
|
183 M | $ 0.32 | -11.32 % | $ 1.1 M |  Schweiz |
 |
Pacific Biosciences of California
PACB
|
1.41 B | $ 1.51 | 7.86 % | $ 383 M | USA |
 |
Bioventus
BVS
|
351 M | $ 6.76 | 1.65 % | $ 423 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | $ 165.21 | - | $ 10.7 B | USA |
 |
Heska Corporation
HSKA
|
844 M | $ 119.99 | - | $ 1.31 B | USA |
 |
Trinity Biotech plc
TRIB
|
120 M | $ 1.06 | -0.47 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
2.46 B | $ 32.79 | 5.37 % | $ 1.9 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | $ 0.17 | -34.28 % | $ 263 K |  Israel |
 |
Biocept
BIOC
|
5.93 M | $ 0.43 | -13.05 % | $ 7.29 M | USA |
 |
VolitionRx Limited
VNRX
|
54.8 M | $ 0.65 | -0.31 % | $ 62.5 M |  Singapore |
 |
Syneos Health
SYNH
|
9.35 B | $ 42.98 | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | $ 0.09 | - | $ 21.2 M | USA |
 |
DermTech
DMTK
|
42.4 M | $ 0.09 | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
75.1 M | $ 0.29 | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
709 M | $ 23.59 | 2.92 % | $ 655 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 16.37 | 5.27 % | $ 464 M | Israel |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 15.53 | 1.94 % | $ 99.4 M | Israel |
 |
PerkinElmer
PKI
|
14.1 B | $ 115.24 | -0.91 % | $ 14.7 B | USA |
 |
OpGen
OPGN
|
9.12 M | $ 1.96 | -16.95 % | $ 1.54 M | USA |
 |
Guardant Health
GH
|
5.84 B | $ 65.32 | 2.96 % | $ 8.02 B | USA |
 |
DexCom
DXCM
|
48.8 B | $ 67.78 | 2.65 % | $ 26.2 B | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | $ 2.12 | -2.3 % | $ 19.4 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 8.82 | -2.17 % | $ 94.9 M | China |
 |
Biomerica
BMRA
|
7.19 M | $ 2.88 | 1.41 % | $ 6.62 M | USA |
 |
Psychemedics Corporation
PMD
|
16.8 M | $ 2.67 | -1.84 % | $ 15.3 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | $ 0.77 | - | $ 7.1 B |  Australia |
 |
Myriad Genetics
MYGN
|
973 M | $ 7.64 | 1.46 % | $ 692 M | USA |
 |
Renalytix AI plc
RNLX
|
22.7 M | $ 0.21 | 5.66 % | $ 22.7 M | Britain |
 |
CareDx, Inc
CDNA
|
521 M | $ 14.79 | 0.82 % | $ 795 M | USA |
 |
IQVIA Holdings
IQV
|
35.7 B | $ 200.6 | -0.13 % | $ 36.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 28.25 | 1.51 % | $ 20 B |  Niderland |
|
Biodesix
BDSX
|
92.1 M | $ 7.75 | 6.16 % | $ 1 B | USA |
 |
T2 Biosystems
TTOO
|
7.78 M | $ 0.12 | -39.35 % | $ 313 K | USA |
 |
Quidel Corporation
QDEL
|
10.6 B | $ 27.86 | 0.56 % | $ 1.17 B | USA |
 |
Agilent Technologies
A
|
42 B | $ 140.81 | 1.62 % | $ 42.8 B | USA |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 0.39 | 5.12 % | $ 11.4 M | USA |
 |
Celcuity
CELC
|
399 M | $ 49.5 | 0.58 % | $ 1.95 B | USA |